本帖最后由 老马 于 2012-1-13 21:20 编辑
8 V5 }# E6 K% j" [% ^5 b+ S; T
! A/ g: Y3 A' d, K1 M9 S" f爱必妥和阿瓦斯丁的比较
. [' n! \5 y) x% c" b: s- E7 n( S
# m2 [$ {) [. g$ D
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
( U$ O/ \1 y# f: H; t4 t" l6 t! J
# j' Y. L% g) c3 F8 g% B
0 s+ f4 a0 h, s' T7 s9 n, Chttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ R6 e# G4 v. ^
==================================================: _5 ?6 [5 w) \5 t/ |
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: L) f7 X9 X5 G$ V$ ^Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 K; Z+ _0 W& U. Z5 e* H2 DResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported., E a: y# N0 M
|